Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)
RegulatorypositiveCosentyxPositive
AI Analysis
Summary
Novartis received a positive CHMP opinion from the EMA recommending marketing authorization for Cosentyx (secukinumab) in polymyalgia rheumatica, positioning it as the first IL-17A inhibitor approved in Europe for this indication. The approval would address a disease with limited advanced treatment options.
Outcome Details
CHMP positive opinion recommending marketing authorization for Cosentyx in polymyalgia rheumatica
Importance:8/10
Sentiment:
0.85
EMACHMPregulatory approvalrheumatologyIL-17A inhibitorfirst-in-classrare disease
Related Companies
Read the original article
Published by GlobeNewswire Pharma on September 18, 2026 2:51 PM